Rhabdoviruses as vaccine platforms for infectious disease and cancer

Zemp, Franz J.; Rajwani, Jahanara; Mahoney, Douglas J.

doi:10.1080/02648725.2018.1474320

Cited by 29 publications

(21 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, genetically simple and pro-inflammatory viruses, such as rhabdoviruses, are suitable for cancer vaccine combinations due to the rapid dissemination of such viruses in secondary lymphoid organ and the TME. Conversely, more complex and slower-replicating viruses, like adenovirus or vaccinia virus which could provide transgene expression persistently, are better suited to deliver checkpoint-blocking antibodies (53,86,140). Second, according to the tumor location and individual patient progress, conventional cancer treatments, including chemotherapy and radiotherapy, could be included in the OV-combined tumor immunotherapy to enhance synergistic effects of anti-tumor immune activation (141)(142)(143).…”

Section: Future Directions For Ov-combined Personalized Cancer Immunomentioning

confidence: 99%

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

The recent successes of tumor immunotherapy approaches, such as immune checkpoint blockade (ICB) and chimeric antigen receptor T cell (CAR-T) therapy, have revolutionized cancer treatment, improving efficacy and extending treatment to a larger proportion of cancer patients. However, due to high heterogeneity of cancer, poor tumor cell targeting, and the immunosuppressive status of the tumor microenvironment (TME), combinatorial agents are required to obtain more effective and consistent therapeutic responses in a wide range of cancers. Oncolytic viruses (OVs) are able to selectively replicate in and destroy tumor cells and subsequently induce systematic anti-tumor immune responses. Thus, they are ideal for combining with cancer immunotherapy. In this review, we discuss the current understanding of OVs, as well as the latest preclinical and clinical progress of combining OVs with cancer immunotherapies, including ICB, CART therapy, bispecific T cell engagers (BiTEs), and cancer vaccines. Moreover, we consider future directions for applying OVs to personalized cancer immunotherapies, which could potentially launch a new generation of cancer treatments.

show abstract

Section: Future Directions For Ov-combined Personalized Cancer Immunomentioning

confidence: 99%

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[77][78][79] It is of course unknown whether, and to what extent, post-exposure prophylaxis prevented the development of EVD, but albeit that these case reports are anecdotal in nature, they are encouraging and provide the basis for current EVD post-exposure recommendations. 76 Vector-specific immunity Although pre-existing anti-VSV immunity is rarely found in humans, 8 anti-vector immunity after vaccination with a VSV vector vaccine might impair vaccine efficacy of future VSV-based vaccines and prime-boost regimens. While data investigating preexisting immunity remain scarce, we recently demonstrated that vaccination with VSV-EBOV induced both vector-specific humoral and cellular immune responses.…”

Section: Correlates Of Protection and Duration Of Immune Responsesmentioning

confidence: 99%

“…7 During the last decade, the recombinant VSV (rVSV) platform has been tested for multiple emerging and neglected viral diseases as well as for therapeutic cancer vaccines in animal studies. 8 Based on the successful establishment of a method to generate VSV from DNA by Rose et al, effective VSV cloning strategies have been implemented 9 and multiple studies revealed the capacity of VSV to express foreign antigens and thus its potential to be used as vaccine candidates. [10][11][12][13] Benefits of the rVSV platform include (reviewed in 14,15 ):…”

Section: Introductionmentioning

confidence: 99%

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Fathi

Dahlke

Addo

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens. ARTICLE HISTORY

show abstract

“…Systemic treatment with oncolytic viruses (OVs) is a promising approach to treat disseminated tumors in different cancer types (1). Vesicular stomatitis virus (VSV), an oncolytic virus of the Rhabdoviridae family, has been demonstrated to be an effective oncolytic agent and vaccine vector platform in clinical trials and animal models (2, 3). However, VSV easily induces a vector-neutralizing antibody response within a few days following administration (4).…”

Section: Introductionmentioning

confidence: 99%

Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum

Pipperger

Koske

Wild

et al. 2019

J Virol

View full text Add to dashboard Cite

Neutralization by antibodies and complement limits the effective dose and thus the therapeutic efficacy of oncolytic viruses after systemic application. We and others previously showed that pseudotyping of oncolytic rhabdoviruses such as maraba virus and vesicular stomatitis virus (VSV) with the lymphocytic choriomeningitis virus glycoprotein (LCMV-GP) results in only a weak induction of neutralizing antibodies. Moreover, LCMV-GP-pseudotyped VSV (VSV-GP) was significantly more stable in normal human serum (NHS) than VSV. Here, we demonstrate that depending on the cell line used for virus production, VSV-GP showed different complement sensitivities in nonimmune NHS. The NHS-mediated titer reduction of VSV-GP was dependent on activation of the classical complement pathway, mainly by natural IgM antibodies against xenoantigens such as galactose-α-(1,3)-galactose (α-Gal) or N-glycolylneuraminic acid (Neu5Gc) expressed on nonhuman production cell lines. VSV-GP produced on human cell lines was stable in NHS. However, VSV-GP generated in transduced human cells expressing α-Gal became sensitive to NHS. Furthermore, GP-specific antibodies induced complement-mediated neutralization of VSV-GP independently of the producer cell line, suggesting that complement regulatory proteins potentially acquired by the virus during the budding process are not sufficient to rescue the virus from antibody-dependent complement-mediated lysis. Thus, our study points to the importance of a careful selection of cell lines for viral vector production for clinical use. IMPORTANCE Systemic application aims to deliver oncolytic viruses to tumors as well as to metastatic lesions. However, we found that xenoantigens incorporated onto the viral surface from nonhuman production cell lines are recognized by natural antibodies in human serum and that the virus is thereby inactivated by complement lysis. Hence, to maximize the effective dose, careful selection of cell lines for virus production is crucial.

show abstract

Rhabdoviruses as vaccine platforms for infectious disease and cancer

Cited by 29 publications

References 67 publications

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum

Contact Info

Product

Resources

About